About emicizumab
Bispecific monoclonal antibody; clotting factor VIII mimetic
Used for
- Routine prevention of bleeding in hemophilia A with or without factor VIII inhibitors
Usual adult dose
Loading: 3 mg/kg under the skin weekly for 4 weeks. Maintenance: 1.5 mg/kg weekly, 3 mg/kg every 2 weeks, or 6 mg/kg every 4 weeks.
Usual dose in children
Same weight-based schedule as adults; used in children, including infants.
Common side effects
- Injection-site reactions
- Headache
- Joint pain
- Diarrhea
Important warnings
- Serious blood clots and thrombotic microangiopathy occurred with activated prothrombin complex concentrate.
- Use caution with bypassing agents; treatment may need adjustment and close monitoring.
- It can interfere with some clotting tests, including activated partial thromboplastin time.
- Not a treatment for an acute bleed.
Pregnancy
Human pregnancy data are limited. Use during pregnancy only when the expected benefit justifies potential risk; effective contraception is advised during treatment and for six months afterward.
Breastfeeding
It is not known whether emicizumab passes into human milk. Consider benefits of breastfeeding and treatment; discuss with a clinician.
Interactions
- Activated prothrombin complex concentrate increases risk of serious blood clots and thrombotic microangiopathy.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.